217 related articles for article (PubMed ID: 10931407)
1. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
4. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[TBL] [Abstract][Full Text] [Related]
5. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
6. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
Du ZD; Di Z; Du JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1841-3. PubMed ID: 19953930
[TBL] [Abstract][Full Text] [Related]
9. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.
Sano T; Kurotobi S; Matsuzaki K; Yamamoto T; Maki I; Miki K; Kogaki S; Hara J
Eur J Pediatr; 2007 Feb; 166(2):131-7. PubMed ID: 16896641
[TBL] [Abstract][Full Text] [Related]
10. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
Peng Q; Wu Q; Chen CH; Hong H; Zhang LY
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
13. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[TBL] [Abstract][Full Text] [Related]
15. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S; Safari M; Amin R
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[TBL] [Abstract][Full Text] [Related]
16. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
Egami K; Muta H; Ishii M; Suda K; Sugahara Y; Iemura M; Matsuishi T
J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442
[TBL] [Abstract][Full Text] [Related]
17. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
20. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.
Nomura Y; Arata M; Koriyama C; Masuda K; Morita Y; Hazeki D; Ueno K; Eguchi T; Kawano Y
J Pediatr; 2010 May; 156(5):786-91. PubMed ID: 20097355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]